Hanna 
kylevAs always, John Green is making an impact on the world with his community. The #PatientsNotPatents effort could spare up to six million lives from the impacts of TB by pressuring J&J to honor the original patent length of a single medication.
https://news.thepublishpress.com/p/john-green
Alliterative/Endless KnotThe #ConnectedAtBirth #etymology of the week is TUBERCULOSIS/THOUSAND #wotd #tuberculosis #thousand #PatientsNotPatents
KamiroseJohn Green helped boost the #PatientsNotPatents movement with his considerable and dedicated audience, but let’s also recognize the young women who spearheaded the movement and who experienced the impact of bedaquiline firsthand.
https://health-e.org.za/2019/02/13/two-women-fight-big-pharma-and-the-worlds-deadliest-disease-2/
Two women vs ‘big pharma’ to fight TB
One hails from Mumbai and the other from Khayelitsha but the pair has teamed up after surviving the planet’s deadliest infectious disease; tuberculosis (TB). Toxic treatment robbed both women of their hearing and a newer, safer, drug is unaffordable leaving many people with the choice between deafness or death.
mikaiah 🌸!! 😊 #patientsnotpatents https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership
13 July 2023 Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB
THANK YOU to everyone who boosted this and who paid attention! J&J DID THE RIGHT THING! #PatientsNotPatents
Kamirose (@[email protected])
I won’t have as much time on Masto today as I have the last few days but since I know my #PatientsNotPatents posts have gained a lot of attention, I think it’s important to post this update: GENERIC BEDAQUILINE WILL BE AVAILABLE WORLDWIDE!!! It’s not a full release of their patent but it IS amazing news for those suffering from MDR-TB in impoverished countries and it WILL save many hundreds of thousands of lives. J&J did the right thing and we should celebrate that! https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
I won’t have as much time on Masto today as I have the last few days but since I know my #PatientsNotPatents posts have gained a lot of attention, I think it’s important to post this update: GENERIC BEDAQUILINE WILL BE AVAILABLE (almost) WORLDWIDE!!!
It’s not a full release of their patent but it IS amazing news for those suffering from MDR-TB in poor countries and it WILL save many hundreds of thousands of lives. J&J did the right thing and we should celebrate that!
https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership
13 July 2023 Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB
Lady Destinee The #StopTB partnership released a statement this morning saying #JohnsonAndJohnson has allowed them to produce generic #bedaquiline and make it available in most developing countries, even in those where the secondary patent is still in effect.
While J&J haven’t released their own statement yet, and this isn’t a complete dropping of their patent, this is a huge step forward in ending TB and deserves to be celebrated.
#PatientsNotPatents #tubercolosis #EndTB
https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership
13 July 2023 Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB
Laura"Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enbable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect."
Wow. 😮
https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
#tuberculosis #PatientsNotPatents
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership
13 July 2023 Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB
I’m proud of us. Don’t let up until/unless they do the right thing. #PatientsNotPatents